Allink Biotherapeutics raises $42m to transform oncology and immunology treatments

Allink Biotherapeutics, a Shanghai-based clinical-stage biotechnology company, has completed a $42 million Series A funding round to accelerate its pipeline of bispecific antibodies and antibody-drug ... Read More